Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEARCH: QL1706 + XELOX in HER2-Negative, Low PD-L1 Advanced Gastric/GEJ Adenocarcinoma
NCT06932068Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Mar 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Qilu Hospital of Shandong University. Started Mar 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06932068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932068.